AVEO Oncology

Executive Summary

AVEO Oncology, a subsidiary of LG Chem, is a Boston-based biopharmaceutical company focused on developing and commercializing targeted cancer therapies. Its lead asset, tivozanib (FOTIVDA), is approved in the US for relapsed/refractory renal cell carcinoma (RCC) and has shown promise in other solid tumors. The company also has a pipeline including ficlatuzumab (anti-HGF) in phase 2 for head and neck squamous cell carcinoma (HNSCC) and other early-stage candidates. As a private entity, AVEO benefits from LG Chem's resources, enabling continued R&D and potential label expansions. Key upcoming catalysts include further clinical data readouts, regulatory decisions, or strategic initiatives that could enhance its valuation or market position.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for ficlatuzumab in HNSCC40% success
• 2026-2027Potential FDA decision on tivozanib in combination therapy for RCC or other indication35% success
• TBDAnnouncement of new partnership or licensing deal for pipeline assets50% success